A new trial, not yet recruiting, will test the combination of ribociclib, a CDK4/6 inhibitor also known as LEE011, and Doxorubicin:
A new trial, not yet recruiting, will test the combination of ribociclib, a CDK4/6 inhibitor also known as LEE011, and Doxorubicin: